| Bioavailability and bioequivalence: focus on physiological factors and variability V Karalis, P Macheras, A Van Peer, VP Shah Pharmaceutical research 25, 1956-1962, 2008 | 83 | 2008 |
| Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease PC Robinson, R Terkeltaub, MH Pillinger, B Shah, V Karalis, E Karatza, ... The American journal of medicine 135 (1), 32-38, 2022 | 73 | 2022 |
| Bioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMA V Karalis, M Symillides, P Macheras Pharmaceutical research 29, 1066-1077, 2012 | 73 | 2012 |
| The integration of artificial intelligence into clinical practice VD Karalis Applied Biosciences 3 (1), 14-44, 2024 | 66 | 2024 |
| Michaelis-Menten kinetics under spatially constrained conditions: application to mibefradil pharmacokinetics K Kosmidis, V Karalis, P Argyrakis, P Macheras Biophysical journal 87 (3), 1498-1506, 2004 | 58 | 2004 |
| 3D-Printed oral dosage forms: Mechanical properties, computational approaches and applications D Karalia, A Siamidi, V Karalis, M Vlachou Pharmaceutics 13 (9), 1401, 2021 | 51 | 2021 |
| Novel scaled average bioequivalence limits based on GMR and variability considerations V Karalis, M Symillides, P Macheras Pharmaceutical research 21, 1933-1942, 2004 | 47 | 2004 |
| Kinetics of anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162b2; a prospective study in 283 health workers E Terpos, IP Trougakos, V Karalis, I Ntanasis-Stathopoulos, S Gumeni, ... Cells 10 (8), 1942, 2021 | 44 | 2021 |
| Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties V Karalis, P Macheras, M Symillides European journal of pharmaceutical sciences 26 (1), 54-61, 2005 | 42 | 2005 |
| Quantitative structure–pharmacokinetic relationships for disposition parameters of cephalosporins V Karalis, A Tsantili-Kakoulidou, P Macheras European journal of pharmaceutical sciences 20 (1), 115-123, 2003 | 41 | 2003 |
| Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations V Karalis, P Macheras, M Bialer CNS drugs 28, 69-77, 2014 | 38 | 2014 |
| Keeping a critical eye on the science and the regulation of oral drug absorption: a review P Macheras, V Karalis, G Valsami Journal of Pharmaceutical Sciences 102 (9), 3018-3036, 2013 | 38 | 2013 |
| Novel scaled bioequivalence limits with leveling-off properties J Kytariolos, V Karalis, P Macheras, M Symillides Pharmaceutical research 23, 2657-2664, 2006 | 38 | 2006 |
| A non-binary biopharmaceutical classification of drugs: the ABΓ system P Macheras, V Karalis International journal of pharmaceutics 464 (1-2), 85-90, 2014 | 36 | 2014 |
| High prevalence of anti-PF4 antibodies following ChAdOx1 nCov-19 (AZD1222) vaccination even in the absence of thrombotic events E Terpos, M Politou, I Ntanasis-Stathopoulos, V Karalis, E Merkouri, ... Vaccines 9 (7), 712, 2021 | 33 | 2021 |
| Drug disposition viewed in terms of the fractal volume of distribution V Karalis, P Macheras Pharmaceutical research 19, 697-704, 2002 | 32 | 2002 |
| Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations V Karalis, G Ismailos, E Karatza Safety science 129, 104842, 2020 | 31 | 2020 |
| Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens E Karatza, G Ismailos, V Karalis Xenobiotica 51 (6), 643-656, 2021 | 30 | 2021 |
| On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline V Karalis, M Symillides, P Macheras European journal of pharmaceutical sciences 44 (4), 497-505, 2011 | 29 | 2011 |
| From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers V Karalis, E Magklara, VP Shah, P Macheras Pharmaceutical research 27, 2018-2029, 2010 | 29 | 2010 |
